^
    1year
    In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin (AACR 2023)
    We developed a fusion protein (GrB-Fc-SD1) composed of human GrB and containing SD1, a novel human single-domain antibody that uniquely targets Region III of the glycoprotein, mesothelin...In addition, screening of an expanded panel of tumor cell lines for in vitro cytotoxicity is currently in progress and will be reported. In vivo efficacy studies against nude mice bearing Capan-2 xenograft models are currently underway and will also be reported.
    Preclinical
    |
    MSLN (Mesothelin) • GZMB (Granzyme B)
    |
    MSLN expression
    |
    GrB-Fc-SD1